BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Arthritis
,
Embryo
,
Amniocentesis
,
Fluoxetine
,
rs2476601
,
FGF21
,
cell-cell adhesion
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CDK 2
Summary
General Info
Curated Studies
Most Correlated Studies
A2780 and MCF7 cancer cell lines treated with CDK, HSP90, and topoisomerase inhibitors
Peripheral blood mononuclear, DU145, and HCT116 cells treated with R547 CDK inhibitor
B cell lymphoma VAL and OCI-LY3 cells treated with CDK-9 inhibitor AZ5576 compound
T cell acute lymphoblastic leukemia MOLT4 cells treated with cyclin-dependent kinase inhibitors
Ovarian cancer OVCAR-3 cells resistant to CDK2 inhibitor PHA-533533
Explore Curated Studies Results
Literature
Most Relevant Literature
Classical MD and metadynamics simulations on back-pocket binders of CDK2 and VEGFR2: a guidepost to …
Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) In…
2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Desig…
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativit…
CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast …
Evaluation of Skin Health and Quality of Life in Patients Receiving Anti-PD1/PDL1/CTLA4 or Cyclin-de…
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Inject…
Palbociclib After CDK and Endocrine Therapy (PACE)
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ